Status:
UNKNOWN
Trial of Low-Dose Naltrexone for Children With Pervasive Developmental Disorder (PDD)
Lead Sponsor:
Hadassah Medical Organization
Collaborating Sponsors:
Jerusalem Institute for Child Development
Conditions:
Pervasive Developmental Disorder
Eligibility:
All Genders
3-6 years
Phase:
PHASE1
PHASE2
Brief Summary
This study will examine the effects of low-dose naltrexone (LDN) on children with autistic spectrum disorders. The investigators hope to show a positive effect on social functioning and language.
Detailed Description
Fifty children aged three to six years will be recruited for the study. They will be randomly assigned to receive either LDN or placebo for two months after which the treatment groups will be switched...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Diagnosis of PDD
Exclusion
Key Trial Info
Start Date :
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT00318162
Last Update
May 3 2006
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Jerusalem Institute for Child Development
Jerusalem, Israel